Comments
Loading...

ALX Oncology Holdings Analyst Ratings

ALXONASDAQ
Logo brought to you by Benzinga Data
$0.4313
-0.00610-1.39%
At close: -
$0.4400
0.008702.02%
After Hours: 7:08 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$34.00
Lowest Price Target1
$1.50
Consensus Price Target1
$9.96

ALX Oncology Holdings Analyst Ratings and Price Targets | NASDAQ:ALXO | Benzinga

ALX Oncology Holdings Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for ALX Oncology Holdings Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Dec 24
3
Jan
3
Mar
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Stifel
Piper Sandler
Jefferies
UBS

1calculated from analyst ratings

Analyst Ratings for ALX Oncology Holdings

Buy NowGet Alert
05/09/2025Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$5 → $2MaintainsBuyGet Alert
03/07/2025Buy NowStifel
Bradley Canino39%
$3 → $1.5MaintainsHoldGet Alert
03/07/2025Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$5 → $5ReiteratesBuy → BuyGet Alert
03/06/2025Buy NowPiper Sandler
Christopher Raymond53%
$8 → $9MaintainsOverweightGet Alert
03/06/2025Buy NowJefferies
Michael Yee55%
$2 → $3UpgradeHold → BuyGet Alert
01/27/2025Buy NowUBS
Colin Bristow38%
$4 → $2.2MaintainsBuyGet Alert
01/24/2025Buy NowCantor Fitzgerald
Li Watsek40%
ReiteratesOverweight → OverweightGet Alert
01/24/2025Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$25 → $5MaintainsBuyGet Alert
12/19/2024Buy NowJefferies
Michael Yee55%
$12 → $2DowngradeBuy → HoldGet Alert
12/18/2024Buy NowCantor Fitzgerald
Li Watsek40%
ReiteratesOverweight → OverweightGet Alert
12/18/2024Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$25 → $25ReiteratesBuy → BuyGet Alert
11/12/2024Buy NowCantor Fitzgerald
Li Watsek40%
Reiterates → OverweightGet Alert
08/16/2024Buy NowUBS
Colin Bristow38%
$25 → $4MaintainsBuyGet Alert
08/13/2024Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$25 → $25ReiteratesBuy → BuyGet Alert
08/12/2024Buy NowCantor Fitzgerald
Li Watsek40%
Reiterates → OverweightGet Alert
08/09/2024Buy NowStifel
Bradley Canino39%
$5 → $3ReiteratesHold → HoldGet Alert
08/01/2024Buy NowStifel
Bradley Canino39%
$14 → $5MaintainsHoldGet Alert
08/01/2024Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$25 → $25ReiteratesBuy → BuyGet Alert
06/10/2024Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$25 → $25ReiteratesBuy → BuyGet Alert
05/29/2024Buy NowCantor Fitzgerald
Li Watsek40%
Reiterates → OverweightGet Alert
04/12/2024Buy NowCantor Fitzgerald
Li Watsek40%
Reiterates → OverweightGet Alert
04/10/2024Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$20 → $20ReiteratesBuy → BuyGet Alert
03/11/2024Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$17.5 → $20MaintainsBuyGet Alert
03/08/2024Buy NowStifel
Bradley Canino39%
$10 → $14DowngradeBuy → HoldGet Alert
03/08/2024Buy NowPiper Sandler
Christopher Raymond53%
$11 → $21MaintainsOverweightGet Alert
12/08/2023Buy NowJefferies
Michael Yee55%
$8 → $18UpgradeHold → BuyGet Alert
11/14/2023Buy NowStifel
Bradley Canino39%
$11 → $10MaintainsBuyGet Alert
10/11/2023Buy NowPiper Sandler
Christopher Raymond53%
$8 → $11MaintainsOverweightGet Alert
10/04/2023Buy NowUBS
Colin Bristow38%
$29 → $27MaintainsBuyGet Alert
10/04/2023Buy NowCantor Fitzgerald
Li Watsek40%
$18 → $23MaintainsOverweightGet Alert
10/03/2023Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$16 → $17.5ReiteratesBuy → BuyGet Alert
09/12/2023Buy NowCantor Fitzgerald
Alethia Young76%
→ $18ReiteratesOverweight → OverweightGet Alert
09/07/2023Buy NowCantor Fitzgerald
Alethia Young76%
→ $18ReinstatesOverweight → OverweightGet Alert
08/14/2023Buy NowCantor Fitzgerald
Alethia Young76%
$22 → $18MaintainsOverweightGet Alert
08/11/2023Buy NowCantor Fitzgerald
Alethia Young76%
$22 → $18MaintainsOverweightGet Alert
08/11/2023Buy NowPiper Sandler
Christopher Raymond53%
$48 → $8MaintainsOverweightGet Alert
08/11/2023Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$30 → $16MaintainsBuyGet Alert
07/24/2023Buy NowCantor Fitzgerald
Alethia Young76%
→ $22ReiteratesOverweight → OverweightGet Alert
05/12/2023Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
→ $30ReiteratesBuy → BuyGet Alert
03/15/2023Buy NowUBS
Colin Bristow38%
$31 → $29MaintainsBuyGet Alert
03/10/2023Buy NowCredit Suisse
Tiago Fauth42%
$38 → $34MaintainsOutperformGet Alert
03/10/2023Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$65 → $30MaintainsBuyGet Alert
11/09/2022Buy NowHC Wainwright & Co.
Swayampakula Ramakanth50%
$80 → $65MaintainsBuyGet Alert
08/09/2022Buy NowCredit Suisse
Tiago Fauth42%
$43 → $38MaintainsOutperformGet Alert
06/06/2022Buy NowStifel
Bradley Canino39%
$35 → $16MaintainsBuyGet Alert

FAQ

Q

What is the target price for ALX Oncology Holdings (ALXO) stock?

A

The latest price target for ALX Oncology Holdings (NASDAQ:ALXO) was reported by HC Wainwright & Co. on May 9, 2025. The analyst firm set a price target for $2.00 expecting ALXO to rise to within 12 months (a possible 354.55% upside). 20 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ALX Oncology Holdings (ALXO)?

A

The latest analyst rating for ALX Oncology Holdings (NASDAQ:ALXO) was provided by HC Wainwright & Co., and ALX Oncology Holdings maintained their buy rating.

Q

When was the last upgrade for ALX Oncology Holdings (ALXO)?

A

The last upgrade for ALX Oncology Holdings Inc happened on March 6, 2025 when Jefferies raised their price target to $3. Jefferies previously had a hold for ALX Oncology Holdings Inc.

Q

When was the last downgrade for ALX Oncology Holdings (ALXO)?

A

The last downgrade for ALX Oncology Holdings Inc happened on December 19, 2024 when Jefferies changed their price target from $12 to $2 for ALX Oncology Holdings Inc.

Q

When is the next analyst rating going to be posted or updated for ALX Oncology Holdings (ALXO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ALX Oncology Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ALX Oncology Holdings was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.

Q

Is the Analyst Rating ALX Oncology Holdings (ALXO) correct?

A

While ratings are subjective and will change, the latest ALX Oncology Holdings (ALXO) rating was a maintained with a price target of $5.00 to $2.00. The current price ALX Oncology Holdings (ALXO) is trading at is $0.44, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch